Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle As Chief Business Officer

Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, today announced that Mary Thistle, former senior vice president, business development at Cubist Pharmaceuticals, has been appointed to the newly created position of chief business officer. Ms. Thistle will report directly to Dimension's CEO Annalisa Jenkins, MBBS, MRCP, and her appointment is effective February 2.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.